ERT, a provider of technology and services to the pharmaceutical, biotechnology and medical device industries, has named Joel Morganroth as the interim CEO of the company, after the retirement of the current CEO Michael McKelve.
Joel Morganroth, currently ERT’s chairman and chief scientific officer, has also been elected by the Board as president and CEO until ERT hires a permanent CEO.
Morganroth has served as the chairman of ERT’s Board of Directors since 1999 and as chief scientific officer since April 2006 and previously served as the company’s CEO from 1993 to March 2001 and also has consulted for ERT since 1977.
Morganroth said that they thank McKelvey for his years of service and wish him well in his future endeavors.
"ERT is a provider of solutions and is well positioned for continued growth. In my expanded role, I will continue to leverage my experience and knowledge of the organization and domain expertise to strengthen our position in clinical research associated with Cardiac Safety, Respiratory and electronic Patient Reported Outcomes (ePRO)," Morganroth said.